References

1. Riordan, J.R.; Rommens, J.M.; Kerem, B.-S.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.;

Plavsic, N.; Chou, J.-L.; Iannuzzi, M.C.; Collins, F.S.; Tsui, L.-C. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066-1073.

2. Kerem, B.-S.; Rommens, J.M.; Buchanan, J.A.; Markiewicz, D.; Cox, T.K.; Chakravarti, A.; Buchwald, M.; Tsui, L.-C. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989, 245, 1073-1080.

3. Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 1993, 329, 1308-1313.

4. Burke, W.; Aitken, J.L.; Chen, S.-H.; Scott, C.R. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. Chest 1992, 102, 506 -509.

5. Grody, W.W.; Cutting, G.; Klinger, K.; Richards, C.S.; Watson, M.S.; Desnick, R.J. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 2001, 3, 149-154.

6. Abeliovich, D.; Lavon, I.P.; Lerer, I.; Cohen, T.; Springer, C.; Avital, A.; Cutting, C.R. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am. J. Hum. Genet. 1992, 51, 951-956.

7. Grody, W.W. Cystic fibrosis: Molecular diagnosis, population screening, and public policy. Arch. Pathol. Lab. Med. 1999, 123, 1041-1046.

8. Rohlfs, E.M.; Zhou, Z.; Sugarman, E.A.; Heim, R.A.; Pace, R.G.; Knowles, M.R.; Silverman, L.M.; Allitto, B.A. The I148T CFTR allele occurs on multiple haplotypes: A complex allele is associated with cystic fibrosis. Genet. Med. 2002, 4, 319-323.

9. Strom, C.M.; Huang, D.; Buller, A.; Redman, J.; Crossley, B.; Anderson, B.; Entwistle, T.; Sun, W. Cystic fibrosis screening using the College panel: Platform comparison and lessons learned from the first 20,000 samples. Genet. Med. 2002, 4, 289 -296.

10. Chong, G.L.; Thibodeau, S.N. A simple assay for the screening of the cystic fibrosis allele in carriers of the phe508 deletion mutation. Mayo Clin. Proc. 1990, 65, 1072-1076.

11. Shuber, A.P.; Skoletsky, J.; Stern, R.; Handelin, B. Efficient 12-mutation testing in the CFTR gene: General model for complex mutation analysis. Hum. Mol. Genet. 1993, 2, 153-158.

12. Wall, J.; Cai, S.; Chehab, F.F. A 31-mutation assay for cystic fibrosis testing in the clinical molecular diagnostics laboratory. Human Mutat. 1995, 5, 333-338.

13. Strom, C.H.; Huang, D.; Chen, C.; Buller, A.; Peng, M.; Quan, F.; Redman, J.; Sun, W. Extensive sequencing of the cystic fibrosis transmembrane conductance regulator gene: Assay validation and unexpected benefits of developing a comprehensive test. Genet. Med. 2003, 5, 9-14.

14. Richards, C.S.; Bradley, L.A.; Amos, J.; Allitto, B.; Grody, W.W.; Maddalena, A.; McGinnis, M.J.; Prior, T.W.; Popovich, B.W.; Watson, M.S. Standards and guidelines for CFTR mutation testing. Genet. Med. 2002, 4, 379-391.

Getting Started With Dumbbells

Getting Started With Dumbbells

The use of dumbbells gives you a much more comprehensive strengthening effect because the workout engages your stabilizer muscles, in addition to the muscle you may be pin-pointing. Without all of the belts and artificial stabilizers of a machine, you also engage your core muscles, which are your body's natural stabilizers.

Get My Free Ebook


Post a comment